Owing to reasons, such as a booming economy andavailability of skilled labor, outsourcing to Asian CMOs, primarily in China,is considered an attractive business model to pharmaceutical developers /sponsors, across the world
Roots Analysis is pleased toannounce the publication of its recent study, titled, “China PharmaceuticalContract Manufacturing Services Market, 2020-2030.”
Thereport features an extensive study of the current market landscape and futureopportunities associated with the pharmaceutical contract manufacturing marketin China. The study also features a detailed analysis, highlighting thecapabilities of pharmaceutical CMOs in this region. Amongst other elements, thereport features:
§ Adetailed assessment of the current market landscape of pharmaceutical contractmanufacturers in China engaged in the development of active pharmaceuticalingredients (APIs), intermediates and finished dosage formulations (FDFs).
§ Adetailed landscape of the pharmaceutical manufacturing facilities in China, includingan analysis based on location of these facilities, highlighting keymanufacturing hubs.
§ Abrief discussion of various regulatory guidelines in China and variouschallenges, related to regulatory scrutiny, faced by pharmaceuticalmanufacturers in China.
§ Detailedprofiles of key players that offer a diverse range of capabilities for themanufacturing of pharmaceutical products in China.
§ Areview of the pharmaceutical manufacturing related initiatives of the top 10big pharma players (shortlisted from thetop companies of 2019 by revenues).
§ Ananalysis of the partnerships and acquisitions that have been established inthis domain, in the recent past.
§ Adetailed capacity analysis based on the installed reactor capacities of themanufacturing facilities in China.
§ Acase study comparing the key characteristics of large molecule and smallmolecule drugs, along with details on the various steps involved in theirrespective manufacturing processes.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
§ KeyGeographical Regions
- Eastern China
- Southern China
- Northern China
§ Typeof Product
- Active Pharmaceutical Ingredients (APIs)
- Drug Products
§ Typeof Drug Product
- Solid
- Liquid / Semi-Solid
- Injectable
- Others
§ Scaleof Operation
- Clinical
- Commercial
§ CompanySize
- Small
- Mid-Sized
- Large / Very Large
Keyplayers covered in the report
§ 2Y-Chem
§ Aurisco Pharmaceutical
§ ChemPartner
§ Dorrapharma
§ Hubei Biocause Pharmaceutical
§ Infoark
§ Ningbo Menovo Pharmaceutical
§ Shandong Xinhua Pharmaceutical
§ Shanghai Acebright Pharmaceuticals
§ STA Pharmaceutical
§ Zhejiang Huahai Pharmaceutical
For more information please click on thefollowing link:
Other Recent Offerings
1. ChinaBiopharmaceutical Contract Manufacturing Market, 2020 – 2030
2. HPAPI and CytotoxicDrugs Manufacturing Market (3rd Edition), 2020-2030
3. Novel coronavirus(COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
